NYSE:PEN Penumbra Q1 2026 Earnings Report $327.14 +2.39 (+0.73%) As of 10:38 AM Eastern This is a fair market value price provided by Massive. Learn more. ProfileEarnings HistoryForecast Penumbra EPS ResultsActual EPS$0.82Consensus EPS $1.06Beat/MissMissed by -$0.24One Year Ago EPS$0.83Penumbra Revenue ResultsActual Revenue$374.76 millionExpected Revenue$370.47 millionBeat/MissBeat by +$4.29 millionYoY Revenue Growth+15.60%Penumbra Announcement DetailsQuarterQ1 2026Date5/6/2026TimeBefore Market OpensConference Call DateWednesday, May 6, 2026Conference Call Time4:00PM ETUpcoming EarningsPenumbra's Q3 2026 earnings is estimated for Wednesday, November 4, 2026, based on past reporting schedules, with a conference call scheduled at 4:30 PM ET. Check back for transcripts, audio, and key financial metrics as they become available.Conference Call ResourcesPress Release (8-K)Quarterly Report (10-Q)Earnings HistoryCompany ProfilePowered by Earnings DocumentsPress Release(8-K)Quarterly report(10-Q) Penumbra Earnings HeadlinesPenumbra: Q2 Earnings SnapshotJuly 30, 2026 | chron.comPenumbra, Inc. Reports Second Quarter 2026 Financial ResultsJuly 30, 2026 | prnewswire.comThe end may be near for these iconic stocksMarc Chaikin, founder of Chaikin Analytics, says two forces - AI disruption and fracturing global trade - are triggering a historic wealth transfer already underway in 2026. Household names like Intuit (-57%), Boston Scientific (-49%), and Tractor Supply (-40%) are cratering, while lesser-known companies like Sandisk (+573%) and Rackspace (+444%) surge. Chaikin has identified specific stocks he believes investors should sell before they fall further - and the names may surprise you. He's also pinpointing a company tapped as Nvidia's self-driving partner and a potential AI megadeal that could split into three high-growth stocks. Stream his free presentation to get every buy and sell recommendation with no membership or credit card required.August 19 at 1:00 AM | Chaikin Analytics (Ad)Magnendo raises $18M to advance robotic platformJuly 27, 2026 | msn.comPenumbra (PEN) Following THUNDERBOLT Debut, Is The Stock A Bargain Or Fairly ValuedJuly 26, 2026 | finance.yahoo.comPenumbra (PEN) Wins FDA Clearance For THUNDERBOLT After Strong Stroke StudyJuly 25, 2026 | finance.yahoo.comSee More Penumbra Headlines Get Earnings Announcements in your inboxWant to stay updated on the latest earnings announcements and upcoming reports for companies like Penumbra? Sign up for Earnings360's daily newsletter to receive timely earnings updates on Penumbra and other key companies, straight to your email. Email Address About PenumbraPenumbra (NYSE:PEN) is a global healthcare company specializing in the development and manufacture of innovative medical devices that address neurovascular and peripheral vascular conditions. The company focuses on products designed to improve patient outcomes in acute ischemic stroke, aneurysm treatment and peripheral thrombectomy. Penumbra’s technologies are used by interventional neuroradiologists, neurosurgeons and interventional cardiologists in hospitals and clinics around the world. At the core of Penumbra’s portfolio is its mechanical thrombectomy platform, which includes aspiration catheters and accessory devices engineered to remove blood clots in acute stroke cases. The company also offers embolization coil systems and flow-diversion devices for the treatment of cerebral aneurysms and vascular lesions. In its peripheral vascular line, Penumbra markets aspiration thrombectomy systems and small-vessel clot retrieval tools designed for limb salvage and treatment of pulmonary embolism. Founded in 2004 by engineer Arani Bose, Penumbra launched its first commercial thrombectomy product in 2007 and has since expanded into new geographies and indications. The company maintains its headquarters in Alameda, California, with additional operations in Europe and Asia Pacific. Over the years, Penumbra has invested in R&D facilities and regulatory approvals to support product launches across more than 100 countries. Under the leadership of President and Chief Executive Officer Adam Elsesser, Penumbra continues to advance its pipeline of next-generation devices, focusing on catheter design, clot visualization and real-time feedback technologies. The company collaborates with academic institutions and clinical specialists to refine procedural techniques and drive evidence generation in stroke and vascular care.View Penumbra ProfileRead more More Earnings Resources from MarketBeat Earnings Tools Today's Earnings Tomorrow's Earnings Next Week's Earnings Upcoming Earnings Calls Earnings Newsletter Earnings Call Transcripts Earnings Beats & Misses Corporate Guidance Earnings Screener Latest Articles Speed Sells: Cerebras Cracks the Silicon CeilingHome Depot Analysts See a Path to $375 and BeyondRTX Stock Gets a Radar Lock on a $23B Navy WinA Star Investor Just Trimmed Amazon—Here's What It meansFabrinet’s Sell-Off May Prove It Is One of AI’s Most Misunderstood StocksThe AI Boom Is Turning This Cable Maker Into a Stock to WatchAmid Legal Risks, This Company Is Still Rated a Buy Upcoming Earnings NetEase (8/20/2026)Alibaba Group (8/20/2026)Ross Stores (8/20/2026)Walmart (8/20/2026)Deere & Company (8/20/2026)PDD (8/24/2026)Bank Of Montreal (8/25/2026)Bank of Nova Scotia (8/25/2026)Heico (8/25/2026)Intuit (8/25/2026) Unlock superior investment research and tools. Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools and reports. Get MarketBeat All Access MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In Email Me a Login Link or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
